Abstract:

The 1% implementation of the Human Genome Project promoted the establishment of China National GeneBank. With the implementation of the National Precision Medicine Program and the improvement of people's health awareness, preventive disease detection and disease avoidance have become the main development areas in the healthcare industry. More and more people regard genetic testing as their first choice for disease diagnosis, which has promoted the rapid development of China's genomics industry. As the promoter of China National GeneBank, BGI has a unique platform advantage. This paper defines the development model based on the National Basic Science Project (National GeneBank) as the platform model. For the R&D enterprises based on the platform model, this paper selects China's largest listed company in genomics industry, BGI, and uses commercial canvas theory to interpret the characteristics and effectiveness of its business model from the perspective of the whole industry chain. Because the platform-based R&D enterprises rely on the national research platform for basic research and commercial operations, they can accumulate a large amount of basic research data and key cooperation institutions, forming platform effects and scale effects that other companies do not have. This paper analyzes the factors affecting the business model of such companies, proposes the theoretical framework of its value evaluation, and presents the follow-up research direction to provide some reference for the management and value evaluation of the same type of enterprises.

Key words: business model, commercial canvas, R&D enterprises, genomics industry, platform mode